Innovent Biologics (1801.HK) — Quick Take

H1 2026 Interim Results: Record Revenue, Profit Inflection & Vision 2030 — Quick Take

Why This Company Now

Healthcare is the dominant sector across both Sazabi VolumeSurge screeners today — 28 of 50 US names and 6 of 50 HK names — and Innovent Biologics is the #1 HK pick, up 9.7% to a record HK$109.80 on HK$4.5B turnover. The catalyst is a blowout H1 2026 interim result (total revenue RMB 8.6B, +45% YoY; IFRS net profit RMB 1.3B, +50% YoY) plus a new "Vision 2030" roadmap targeting RMB 35–40B revenue. Founder/CEO Michael Yu frames 2026 as Innovent's "best strategic window to date" — backed by US$34B of cumulative out-licensing deals with Takeda, Eli Lilly and Pfizer — as the company pushes its third transformation from China leader to global premier biopharma.

Financial Snapshot

*Operating margins are approximations (pre-2025 loss-making years). IFRS net income shown. 2025 marked first full year of profit; H1 2026 non-IFRS net profit RMB 1.7B (+41%). Cash reserves RMB 30.2B (~US$4.5B) as of 31 Jul 2026.

Bull vs Bear

Year	Revenue	Rev Growth	Op Margin	Net Income
2022	RMB 4.56B	+7%	~-48%*	-RMB 2.18B
2023	RMB 6.21B	+36%	~-17%*	-RMB 1.03B
2024	RMB 9.42B	+52%	~-8%*	-RMB 0.75B
2025	RMB 13.04B	+38%	~+6% (EBITDA 15.3%)	+RMB 0.81B
H1 2026	RMB 8.60B	+45%	~+15%*	+RMB 1.30B

✅ Bull Case

Dual-engine growth: oncology franchise (TYVYT + next-gen IO/ADC assets IBI363, IBI343) plus general biomedicine (Mazdutide — world's first GCG/GLP-1 dual agonist for obesity & T2D; SYCUME for thyroid eye disease; SINTBILO PCSK9) drove +45% revenue and +50% profit in H1 2026.
Unmatched global validation: US$34B aggregate deal value with Takeda, Lilly and Pfizer (>30% of all China out-licensing value in the period), with 3 late-stage assets carrying a combined >US$60B TAM entering global Phase 3.
Scale + balance sheet: RMB 30.2B cash (~US$4.5B), positive operating cash flow, 140,000L capacity (~20% of China's biologics) and a fresh EMA GMP certificate; Vision 2030 targets RMB 35–40B revenue with top-tier margins.

🔴 Bear Case

Rich valuation: ~45x forward non-IFRS earnings (trailing IFRS P/E ~200x) prices in years of flawless execution; the stock is at a record high, so any slip hits hard.
China pricing & competition: NRDL price cuts, VBP pressure and a crowding domestic field in both PD-1 and GLP-1/oral obesity (multiple once-daily oral GLP-1 rivals) can compress margins on the core franchise.
Global build-out unproven: US/EU commercial infrastructure must be built from scratch; the 2030 plan leans on partner-dependent milestones (Takeda, Ollin) and heavy R&D spend across five global Phase 3 programs that can slip.

Verdict

Innovent is the rare Chinese biopharma that has crossed from loss-making scale-up to full profitability while simultaneously validating its pipeline at global-pharma prices — the US$34B partner book is the strongest possible third-party endorsement. The risk is that a ~45x forward multiple on a record high demands continued beat-and-raise, and China's GLP-1/PD-1 pricing war is real. For a patient, global-mandated healthcare investor, the asymmetry still looks interesting — but it's a growth stock, not a value entry.